Skip to Main Content
NAACCR Data Dictionary
Data Standards and Data Dictionary
  1. Home
  2. Data Dictionary
  3. Version 25

Version 25
Data Item #1174: PD-L1

* indicates required field

Length: 5
Source of Standard: NAACCR
Section Name: Stage/Prognostic Factors
Year Implemented: 2025
Version Implemented: 25
Record Types: I, M, C, A

XML NAACCR ID: pdl1

Parent XML Element: Tumor

Required Status:

NPCR Collect: RS* - Required, site specific; when available
CoC Collect: RS - Required, site specific
SEER Collect: RS - Required, site specific
CCCR Collect: RS* - Required, site specific; when available

Description:

The absence or presence of PD-L1 expression determines if the tumor will respond to treatment with a targeted inhibitor (immunotherapy). PD-L1 is done for Non-small cell lung cancers (NSCLC).

Rationale:

PD-L1 is recommended by treatment guidelines for lung cancer to determine if the patient may benefit from checkpoint inhibitor drugs (immunotherapy). It is a new data item for cases diagnosed 1/1/2025+.

Item Data Type:

text

Allowable Values

0.0, 0.1-100.0, XXX.2, XXX.3, XXX.4, XXX.7, XXX.8, XXX.9

Codes:

0.0

No PD-L1 expression identified

Tumor Proportion Score (TPS) = 0%

0.1-100.0

0.1-100.0 PD-L1 expression

Tumor Proportion Score (TPS) = 0.1%-100.0%

XXX.2

PD-L1 expression absent AND

Tumor Proportion Score (TPS) stated as negative

XXX.3

PD-L1 expression present AND

Tumor Proportion Score (TPS) stated as low

XXX.4

PD-L1 expression present AND

Tumor Proportion Score (TPS) stated as high/positive

XXX.7

Test ordered, results not in chart

XXX.8

Not applicable: Information not collected for this case
(If this item is required by your standard setter, use of code 8 will result in an edit error)

XXX.9

Not documented in medical record

No microscopic confirmation of tumor

PD-L1 cannot be determined

PD-L1 not assessed or unknown if assessed

Blank

NA - Diagnosis year is prior to 2025

Code Notes:

Note 1: This SSDI is effective for diagnosis years 2025+. 

  • For cases diagnosed 2018-2024, leave this SSDI blank

Note 2: Physician statement PD-L1 can be used to code this data item when no other information is available.

Note 3: The absence or presence of PD-L1 expression determines if the tumor will respond to treatment with a targeted inhibitor. PDL-1 is done for Non-Small Cell lung cancers (NSCLC)

Note 4: If neoadjuvant therapy is given, record the assay from tumor specimens prior to neoadjuvant therapy. 

  • If neoadjuvant therapy is given and there are no PD-L1 results from pre-treatment specimens, report the findings from post-treatment specimens